TABLE 2.
Mapped and identified modifiers
Gene | Cytological site | Accession no. | Allelea | Mutationsb | Phenotypes in Psn mutant backgroundcd | Gene identification methods (maximal interval defined by SNPs, phenotype mapped)e |
---|---|---|---|---|---|---|
dac | 36A1 | NM_165161 | MEE-2* | 367–794 DEL and FS | Enhanced eye | Meiotic (40 kb, enhanced eye) and noncomplementation with dac[3] and dac[4] |
MHE-1 | Y259N | Enhanced eye | ||||
SFE-8* | C272Y; 887–1074 DEL and FS | Enhanced eye | ||||
dp | 24F4–25A1 | NM_175960.2 | MFE-1* | Not determined | Notal pits | Meiotic (7 Mb, notal pits) and noncomplementation with CyO dp[lvI], Df(2L)dp-h25, dp[olvR], Tp(2;3)dp[h27], and dp[olvDG10] |
PGE-8 | Not determined | Enhanced eye | ||||
PHE-5 | Not determined | Lethal | ||||
PIE-10* | Not determined | Notal pits | ||||
eya | 26E1–E2 | NM_078768 | SJE-1 | Translocation | Enhanced eye | Cytology, in situ |
SLE-2 | Not determined | Enhanced eye | ||||
γ-Tub23C | 23C3–C4 | NM_057456 | bmps1d* | M382I | Enhanced eye, wing bumps and notching | Meiotic (26.1 kb, enhanced eye) |
bmps2* | M382I | Enhanced eye, wing bumps and notching | ||||
bmps3 | P358L | Enhanced eye, wing bumps and notching, vein thickening | ||||
bmps4 | P358L | Enhanced eye, wing bumps and notching, vein thickening | ||||
bmps5 | P358L | Enhanced eye, wing bumps and notching, vein thickening | ||||
so | 43C1 | NM_057385 | SHE-7* | R274Q | Enhanced eye | Meiotic (48 kb, enhanced eye) |
SKE-1d* | 281–416 DEL | Enhanced eye | ||||
Spt5 | 56D5–D7 | NM_144353 | MGE-3* | K236* | Enhanced eye | Meiotic (36.2 kb, enhanced eye) |
SIE-27* | Q632* | Enhanced eye | ||||
S | 21E2–E3 | NM_078726 | 16 alleles | Not determined | Enhanced eye | Noncomplementation with S[BTE] |
vg | 49E1 | NM_078999 | PHE-4 | Not determined | Wing notching | Noncomplementation with Df(2R)vg133 and vg[1] |
SDE-1 | Splice @435 | Enhanced eye, wing notching | ||||
SGE-4 | Q349* | Wing notching | ||||
SGE-11 | Not determined | Enhanced eye, wing notching | ||||
AP-47 | 85D24 | NM_141649 | SAE-10* | S366N | Enhanced eye, vein thickening | Meiotic (85 kb, enhanced eye) |
SHE-11* | 146–158 DEL and FS | Enhanced eye, vein thickening, low penetrance pupal lethal | ||||
Dl | 92A1–2 | NM_057916 | MIE-19 | W252* | Lethal | Meiotic (86 kb, enhanced eye) and noncomplementation with known alleles |
MIE-22* | C433S; C506W | Enhanced eye, vein thickening | ||||
PFE-5 | C488Y | Lethal | ||||
PFE-6 | 1–20 DEL | Enhanced eye, vein thickening | ||||
PGE-2 | 1st exon deleted | Enhanced eye, vein thickening | ||||
SDE-4* | C538R | Enhanced eye, vein thickening | ||||
SHE-5 | C362Y | Wings held out, wing notching | ||||
SHE-11 | Splice @124 | Enhanced eye, vein thickening, low penetrant pupal lethal | ||||
SIE-36 | Translocation | Vein thickening, low penetrant pupal lethal | ||||
gl | 91A3 | NM_057506 | SAE-9d | R466* | Enhanced eye | Noncomplementation with gl[2], gl[3] |
H | 92F3 | NM_079694 | PFE-1 | Not determined | Bristle shaft to socket transformations, vein loss | Noncomplementation with known alleles |
PGE-1 | Not determined | Bristle shaft to socket transformations, vein loss | ||||
PGE-4 | Not determined | Bristle shaft to socket transformations, vein loss | ||||
PGE-6 | Not determined | Bristle shaft to socket transformations, vein loss | ||||
SDS-1 | Not determined | Suppressed eye, bristle shaft to socket transformations, vein loss | ||||
SLS-1 | Not determined | Suppressed eye, bristle shaft to socket transformations, vein loss | ||||
hh | 94E1 | NM_079735.3 | PIE-7* | G257D | Enhanced eye, extra vein material between veins 2 and 3 | Meiotic (161 kb, enhanced eye) and noncomplementation with known alleles |
SCE-2 | Translocation | Enhanced eye, wing notching | ||||
SFE-4 | 284–462 DEL and FS | Enhanced eye | ||||
SGE-2 | N141I | Enhanced eye | ||||
SHE-2* | S286N | Enhanced eye | ||||
SLE-1* | Uncharacterized deletion | Enhanced eye | ||||
kkv | 83A1 | NM_079509 | A1 | G824D | Enhanced eye | Cytology, in situ on a transposition that fails to complement this groupf |
BM1 | P764N | Enhanced eye | ||||
SIE-29 | I1043N | Enhanced eye | ||||
Nsf2 | 87F15 | NM_176499 | A6d* | A597V | Enhanced eye | Meiotic (24 kb, enhanced eye) |
A15* | 555–641 DEL and FS | Enhanced eye | ||||
nct | 96B1 | NM_143040 | PIE-6 | Point mutation in 3′ UTR | Enhanced eye | Meiotic (1.46 Mb, enhanced eye) |
SGE-3 | K476* | Enhanced eye | ||||
SGE-8 | Q177* | Enhanced eye, wing vein thickening and notching | ||||
SGE-9 | R273C | Enhanced eye, wing vein thickening and notching | ||||
SGE-10* | Uncharacterized deletion | Enhanced eye | ||||
SIE-28* | Not determined | Enhanced eye, wing vein thickening and notching | ||||
SIE-22 | C272Y | Enhanced eye, wing notching, missing microchaetae | ||||
Opa | 82E1 | NM_079504 | A3 | Uncharacterized deletion | Enhanced eye, tufted vibrissae | Cytology, in situ |
B28 | Y275N | Enhanced eye, tufted vibrissae | ||||
SIE-19 | Y242D | Enhanced eye, tufted vibrissae | ||||
SIE-24 | Q104* | Enhanced eye, tufted vibrissae | ||||
SJE-2 | Translocation | Enhanced eye, tufted vibrissae, wing notching | ||||
SKE-5 | Uncharacterized deletion | Enhanced eye, tufted vibrissae | ||||
Psn | 77C3 | NM_079460 | 9 | L499Q | Enhanced eye | Sequencing lethal and viable noncomplementers |
DIE-2g | Q244* | Lethal | ||||
MIE-5g | Not determined | Lethal | ||||
MIE-12g | Q523* | Lethal | ||||
MIE-15g | Not determined | Lethal | ||||
PIE-11g | G446S | Lethal | ||||
SIE-5g | D110L | Lethal | ||||
R | 62B7 | NM_057509 | PIE-6d | L120F | Enhanced eye | Noncomplementation with R[1] |
Ras85D | 85D21 | NM_057351 | MAE-2* | M67I | Enhanced eye | Meiotic (106 kb, enhanced eye) and noncomplementation with Ras85[D06677] and Ras85[D05703] |
MDE-7* | G60S | Enhanced eye |
Meiotically mapped alleles are indicated by an *.
The mutation for each allele is indicated. Amino acid numbers are derived from the reference sequence listed in the accession number column. “Splice @” is defined as a nucleotide change in the donor/acceptor “GU/AG” sequence at the referenced amino acid position. “DEL” refers to a deletion of the referenced amino acids and “FS” refers to a predicted frameshift.
Psn background: screen A, Psn143/+ (alleles: 9, bmps1, bmps2, A1, BM1. A6, A15, A3, B28); screen B, Psn9/Psn143 (all other alleles).
Phenotypes in a Psn wild-type background were not assessed, with the following exceptions: NSF2A6 (see results), γ-Tub23C (see results), glSAE-9 (homozygous viable and displays a very small eye), soSKE-1 (homozygous viable and displays a very small eye and loss of ocelli), and RPIE-6 (homozygous viable and displays slightly reduced and severely rough eyes).
Method(s) of gene identification are indicated for each group. Final meiotic mapping interval and the phenotype mapped are indicated in parentheses. The alleles meiotically mapped for each group are indicated by an * in the “Allele” column.
Three additional alleles of kkv were found by testing kkvA1 and kkvBM1 for noncomplementation with a set of lethal mutations within the 82F region recovered by Carpenter (1999). One of these alleles consisted of an X-ray-induced transposition [T(2;3)82Fh2], which was used to cytologically locate the gene by in situ hybridization analysis on polytene chromosomes.
These alleles also carry the Psn9 L499Q mutation in cis to the reported mutation.